Gackky
2021-12-18
why fell, due to omircon
why raise , due to omircon
Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
Venus_M
2021-12-19
Venus_M
因为ppl转储而下跌
上涨cos ppl追高
的兴奋
交易
什么也没有了～
APP内打开
发表看法
3
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":699218451,"tweetId":"699218451","gmtCreate":1639807847647,"gmtModify":1639807849439,"author":{"id":3574326723774097,"idStr":"3574326723774097","authorId":3574326723774097,"authorIdStr":"3574326723774097","name":"Gackky","avatar":"https://static.tigerbbs.com/5898b44bf5a31bf2b9d4e37227ed8177","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":183,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>why fell, due to omircon</p><p>why raise , due to omircon</p></body></html>","htmlText":"<html><head></head><body><p>why fell, due to omircon</p><p>why raise , due to omircon</p></body></html>","text":"why fell, due to omircon why raise , due to omircon","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/699218451","repostId":1109831591,"repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note. <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a> and <a href=\"https://laohu8.com/S/JNJ\"><b>Johnson & Johnson</b></a> both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b> analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech <b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-18 13:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note. <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a> and <a href=\"https://laohu8.com/S/JNJ\"><b>Johnson & Johnson</b></a> both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b> analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech <b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1,"symbols_score_info":{"PFE":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":1264,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":7044106,"commentId":"7044106","gmtCreate":1639915001265,"gmtModify":1639915001265,"authorId":3566385558470298,"author":{"id":3566385558470298,"idStr":"3566385558470298","authorId":3566385558470298,"name":"Venus_M","avatar":"https://static.tigerbbs.com/525433622d774840840ddaacaf2281d2","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":699218451,"objectIdStr":"699218451","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"因为ppl转储而下跌<br>上涨cos ppl追高\n<br>的兴奋\n<u>交易</u>","text":"因为ppl转储而下跌<br>上涨cos ppl追高\n<br>的兴奋\n<u>交易</u>","html":"因为ppl转储而下跌<br>上涨cos ppl追高\n<br>的兴奋\n<u>交易</u>","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/699218451"}
精彩评论
上涨cos ppl追高
的兴奋 交易